[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neurogenic-lower-urinary-tract-dysfunction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neurogenic-lower-urinary-tract-dysfunction":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,53,90,111],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":32,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100643017","early-phase-1-coupled-gentamicin-lactobacillus-rhamnosus-in-nlutd-100643017",false,"NCT07643974","Coupled Gentamicin-Lactobacillus Rhamnosus in NLUTD","Effect of Dose Timing of Coupled Intravesical Gentamicin and Lactobacillus Rhamnosus LGG on Success and Length of Colonization in Men and Women With SCI\u002FD and NLUTD","Inclusion Criteria:\n\n* Neurologic diagnosis\n* ≥18 years old\n* Neurogenic bladder for at least 6 months\n* No USQNB-IC A, B1, or B2 symptoms\n* No currently diagnosed UTI (within 24 hours of initiating instillations)\n* Community dwelling (not in acute hospital setting)\n\nExclusion Criteria:\n\n* Known genitourinary pathology beyond NLUTD (i.e. kidney stones, bladder stones, vesicoureteral reflux, etc.)\n* Use of prophylactic antibiotics or any antibiotics within 2 weeks of beginning instillations\n* Instillation of intravesical agents other than saline bladder wash\n* Immunodeficiency\n* Psychologic or psychiatric conditions influencing the ability to follow instructions\n* Allergy to ampicillin, daptomycin, gentamicin\u002Fgentamycin, or probiotics\n* Participation in another study which could confound results","ALL","18 Years",{"count":19,"type":20},48,"ESTIMATED","INTERVENTIONAL",[23],"EARLY_PHASE1","The main objective of the proposed research study is to determine in men and women with spinal cord injury\u002Fdisease and neurogenic bladder whether the dose of coupled gentamicin \\& Lactobacillus rhamnosus GG affects the recolonization of the bladder, and whether the rate of success differs by sex. Secondary objectives include determining whether that recolonization lasts 7, 14, or 28 days; and safety of the coupled gentamicin \\& Lactobacillus instillations.",[26,27,28,29,30,31],"Spinal Cord Injury","Neurogenic Bladder (NB)","Neurogenic Lower Urinary Tract Dysfunction","Multiple Sclerosis","Spina Bifida","Urinary Tract Infection(UTI)",[33,34,35,36,37,38,39],"gentamicin","gentamycin","lactobacillus","spinal cord injury","spinal cord disease","urinary tract infection","neurogenic bladder","NOT_YET_RECRUITING","2026-06-08",{"date":43,"type":44},"2026-06-12","ACTUAL",{"date":46,"type":20},"2026-06",{"date":48,"type":20},"2027-09",{"name":50,"class":51},"Medstar Health Research Institute","OTHER",2,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":59,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":60,"targetDuration":4,"studyType":21,"phases":62,"briefSummary":64,"conditions":65,"keywords":67,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":89},"100642982","radio-frequency-rf-bladder-monitor-100642982","NCT07639541","Radio-frequency (RF) Bladder Monitor","Inclusion Criteria:\n\n* Age \\> 18\n* Able\u002Fwilling to sit (or stand) in place for the time it takes for bladder to fill once.\n* No implanted devices\n* Able to toilet\u002Fvoid independently\n* No pregnancy\n\nExclusion Criteria:\n\n* Age \\\u003C 18\n* Implanted devices (e.g., pacemakers)\n* Unable to toilet without assistance\n* Unable to stay relatively still for the time it takes bladder to fill once\n* Pregnancy",true,{"count":61,"type":20},40,[63],"NA","The goal of this pilot feasibility study is to evaluate a wearable microwave (MW)-based bladder monitoring system in adult volunteers and those with spinal cord injury (SCI) who use self-catheterization for bladder management. The study aims to learn whether the device can monitor bladder filling and estimate bladder volume non-invasively.\n\nThe main questions the study aims to answer are:\n\n1. Can the MW-based monitoring system distinguish between non-full and full bladder states?\n2. How accurately do MW-based bladder volume estimates agree with ultrasound bladder scans and voided urine volumes?\n3. Is the wearable monitoring system feasible, comfortable, and usable for individuals with SCI?\n\nParticipants will:\n\n1. Complete questionnaires about bladder symptoms and quality of life\n2. Wear up to six non-invasive MW sensors on the lower pelvic region\n3. Undergo two bladder filling and voiding cycles during the study visit\n4. Have MW measurements collected approximately every five minutes during bladder filling\n5. Undergo ultrasound bladder scans and bladder volume measurements for comparison\n6. Complete a post-study usability and comfort survey",[66,28,27],"Spinal Cord Injuries (SCI)",[26,68,28,69,70,71,72,73,74,75,76,77,78,79],"Neurogenic Bladder","Bladder Monitoring","Bladder Management","Microwave Sensing","Radio-Frequency Sensing","Wearable Medical Device","Bladder Fullness Detection","Bladder Volume Estimation","Non-Invasive Monitoring","Assistive Technology","Pilot Feasibility Study","Urology","2026-06-05",{"date":82,"type":44},"2026-06-10",{"date":84,"type":20},"2026-07-01",{"date":86,"type":20},"2027-03-31",{"name":88,"class":51},"McGill University Health Centre\u002FResearch Institute of the McGill University Health Centre",1,{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":97,"targetDuration":4,"studyType":99,"phases":4,"briefSummary":100,"conditions":101,"keywords":4,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":110,"locationsCount":89},"100622974","patient-and-caregiver-perspectives-on-intravesical-instillations-for-urinary-symptoms-100622974","NCT07390591","Patient and Caregiver Perspectives on Intravesical Instillations for Urinary Symptoms","Intravesical Gentamicin Coupled With Lactobacillus Rhamnosus for Urinary Health- Early Career","Inclusion Criteria:\n\nCriteria for patients:\n\n* Age 18+\n* Diagnosis of NLUTD\n* Chronic catheter usage (minimum 6 months), either intermittent catheterization or indwelling catheter\n* Community-dwelling\n* Experience using intravesical Lactobacillus, gentamicin, or combination of the two\n\nCriteria for caregivers:\n\n* Age 18+\n* Care for patient with diagnosis of NLUTD\n* Care for patient who has used catheters chronically (minimum 6 months)\n* Experience facilitating patients' use of intravesical Lactobacillus, gentamicin, or combination of the two\n\nExclusion Criteria:\n\n* Psychiatric or psychologic conditions impacting ability to consent",{"count":98,"type":20},60,"OBSERVATIONAL","The goal of this observational qualitative study is to learn about the experiences and perspectives of patients with neurogenic lower urinary tract dysfunction (NLUTD) and their caregivers regarding different types of intravesical instillations used for urinary health. The study aims to understand the perceived benefits, challenges, and opportunities related to Lactobacillus-only, gentamicin-only, and combined gentamicin-Lactobacillus instillations. The main question this study seeks to answer is:\n\n1\\. Determine patient and caregivers' preferences, and overall experiences regarding intravesical therapeutics for urinary symptoms and UTI\n\nResearchers will compare responses from four groups: participants who have used Lactobacillus-only instillations, gentamicin-only instillations, combined gentamicin-Lactobacillus instillations, and caregivers who have experience supporting instillations.\n\nParticipants will take part in a one-hour semi-structured interview and may be contacted for brief follow-up discussions to clarify findings. Interviews will be audio-recorded, transcribed, and analyzed using qualitative data software to identify themes related to treatment preferences and acceptability.",[102,28,68],"Spinal Cord Injuries","RECRUITING","2026-01-28",{"date":106,"type":44},"2026-02-05",{"date":108,"type":44},"2025-06-19",{"date":48,"type":20},{"name":50,"class":51},{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":115,"acronym":116,"eligibilityCriteria":117,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":118,"targetDuration":4,"studyType":99,"phases":4,"briefSummary":120,"conditions":121,"keywords":123,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":89},"100606281","cost-profile-and-budget-implications-of-rechargeable-versus-non-rechargeable-sacral-neuromodulation-devices-for-neurogenic-lower-urinary-tract-dysfunction-100606281","NCT07173517","Cost Profile and Budget Implications of Rechargeable Versus Non-rechargeable Sacral Neuromodulation Devices for Neurogenic Lower Urinary Tract Dysfunction","SNM、NLUTD","Inclusion Criteria:\n\n* male and female patients with neurogenic lower urinary tract dysfunction who had failed conventional treatment\n* obstructive urinary retention and contraindications to SNM",{"count":119,"type":20},268,"Traditional sacral neuromodulation devices are not rechargeable. In recent years, new rechargeable sacral neuromodulation devices have been developed and put into the market. The aim of this study was to evaluate the cost savings of a rechargeable sacral neuromodulation device versus a non-rechargeable sacral neuromodulation device for the treatment of neurogenic lower urinary tract dysfunction.",[122,28],"Rechargeable Sacral Neuromodulation Device",[124,125,126,127],"neurogenic lower urinary tract dysfunction","cost-savings","sacral neuromodulation","rechargeable","2025-09-07",{"date":130,"type":44},"2025-09-15",{"date":132,"type":20},"2025-10-01",{"date":134,"type":20},"2026-04-30",{"name":136,"class":51},"Qilu Hospital of Shandong University"]